Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 6/2010

01-12-2010 | Introduction to Review Articles

Tumor-infiltrating lymphocytes and hepatocellular carcinoma

Author: Yoshihiko Maehara

Published in: International Journal of Clinical Oncology | Issue 6/2010

Login to get access

Excerpt

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors around the world [1] and in Japan. Although hepatic resection, liver transplantation, chemoembolization, ethanol injection, thermal ablation and new tyrosine kinase inhibitors such as sorafenib are available for treatment, the overall survival of patients with HCC remains poor. …
Literature
1.
Ince N, Wands JR (1999) The increasing incidence of hepatocellular carcinoma. New Engl J Med 340:798–799PubMedCrossRef
Metadata
Title
Tumor-infiltrating lymphocytes and hepatocellular carcinoma
Author
Yoshihiko Maehara
Publication date
01-12-2010
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 6/2010
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-010-0125-y

Other articles of this Issue 6/2010

International Journal of Clinical Oncology 6/2010 Go to the issue

Case Report

A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment

Original Article

Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial

Case Report

Non-muscle invasive bladder cancer with concomitant vaginal urothelial carcinoma: a case report and review of the literature

Special Article

Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition

Original Article

Review of primary unknown cancer: cases referred to the National Cancer Center Hospital East

Acknowledgments

List of reviewers 2009–2010
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits